Adverse cardiac remodeling is absent in patients with true controlled resistant hypertension.

Resistant hypertension (RHTN), defined as blood pressure (BP) that is uncontrolled with ≥3 medications, including a long-acting thiazide diuretic, also includes a subset with BP that is controlled with ≥4 medications, so-called controlled RHTN. This resistance is attributed to intravascular volume excess. Patients with RHTN overall have a higher prevalence of left ventricular hypertrophy (LVH) and diastolic dysfunction compared to patients with non-RHTN.

Incidence and predictors of MRI scan utilization in MRI-conditional pacemaker recipients: A multicenter experience.

Background: Patient characteristics, higher device cost, and vendor contracts likely prevent use of magnetic resonance imaging (MRI)-conditional pacemakers (MRC) in all pacemaker (PM)-eligible patients. We sought to identify the incidence and predictors of MRI scan utilization in MRC recipients.

Methods: Patients receiving an MRC or non-MRI-conditional PM (NMRC) at four centers were included.

Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.

Refractory hypertension (RfHTN) is an extreme phenotype of antihypertensive treatment failure defined as lack of blood pressure control with ≥5 medications, including a long-acting thiazide and a mineralocorticoid receptor antagonist. RfHTN is a subgroup of resistant hypertension (RHTN), which is defined as blood pressure >135/85 mm Hg with ≥3 antihypertensive medications, including a diuretic. RHTN is generally attributed to persistent intravascular fluid retention.

Cost-effectiveness analysis of magnetic resonance imaging-conditional pacemaker implantation: Insights from a multicenter study and implications in the current era.

Background: Magnetic resonance imaging (MRI)-conditional pacemakers (M-PPMs) grant patients greater accessibility to MRI scans. The cost-effectiveness of implanting M-PPM is unknown.

Objective: The purpose of this study was to determine the cost-effectiveness of M-PPM implantation.